KNSA
Kiniksa Pharmaceuticals Interna
$79.03
+0.71%
2026-08-21
About Kiniksa Pharmaceuticals Interna
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Key Fundamentals
P/E Ratio
77.53
Forward P/E
47.45
EPS (TTM)
$0.99
ROE
14.0%
Revenue Growth (YoY)
55.4%
Profit Margin
9.6%
Debt/Equity
1.36
Price/Book
9.15
Beta
0.09
Market Cap
$5.99B
Avg Volume (10D)
455K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$82.94
60D Low
$46.10
Avg Volume
729K
Latest Close
$79.03
Get breakout alerts for KNSA
Sign up for Breakout Scanner to receive daily notifications when KNSA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Kiniksa Pharmaceuticals Interna (KNSA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KNSA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KNSA operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.